UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~April 291, 2026

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)


Nevada	001-37823	99-0360497
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10500 University Center Dr., Suite 110
Tampa, Florida 33612
(Address of Principal Executive Offices, including zip code)
Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

     
Title of each class

     Trading
Symbol(s)

Name of each exchange on which registered

     Common Stock, $0.001 par value per share
 
     HURA

     The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 32.0102 Results ~~Notice~~ of ~~Delisting~~Operations orand ~~Failure~~Financial ~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Condition.

On ~~January~~April 291, 2026, TuHURA Biosciences, Inc. (the “Company”) ~~received~~or ~~a letter from The Nasdaq Stock Market LLC (~~“~~Nasdaq~~TuHURA”) ~~indicating~~issued ~~that~~a ~~the~~press ~~Company’s~~release ~~consolidated~~reporting ~~closing~~its ~~bid~~financial ~~price~~results ~~has been below $1.00 per share~~ for 35the ~~consecutive~~year ~~business~~ended ~~days~~December ~~as of January 28~~31, ~~2026~~2025, and ~~that,~~providing ~~therefore,~~a ~~the~~corporate ~~Company~~update. isA ~~not~~copy inof ~~compliance~~the ~~with~~press ~~Nasdaq~~release ~~Listing Rule 5550(a)(2), which~~ is ~~the~~attached ~~minimum~~hereto ~~bid~~as ~~price~~Exhibit ~~requirement for continued listing on The Nasdaq Capital Market~~99.1 ~~The~~and ~~notice~~is ~~does~~incorporated ~~not~~by ~~result~~reference ~~in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market.~~herein

~~Pursuant~~The toinformation ~~Nasdaq~~contained ~~Listing~~in ~~Rule~~this ~~5810(c)(3)(A)~~Current Report, ~~the~~including ~~Company~~Exhibit ~~has~~99.1 ~~automatically~~attached ~~been~~hereto, ~~afforded~~is abeing ~~180-calendar~~furnished, ~~day~~shall ~~grace~~not ~~period,~~be ordeemed ~~until~~“filed” ~~July~~for ~~28,~~any ~~2026~~purpose, toand ~~regain~~shall ~~compliance.~~not ~~The~~be ~~continued~~deemed ~~listing~~incorporated ~~standard~~by ~~will~~reference bein ~~met~~any iffiling under the ~~consolidated~~Securities ~~closing~~Act ~~bid price~~ of ~~the~~1933, ~~Company’s~~as ~~common~~amended, ~~stock~~or isthe atSecurities ~~least~~Exchange ~~$1.00~~Act ~~per~~of ~~share~~1934, ~~for~~as aamended, ~~minimum~~except ofas ~~ten~~expressly ~~consecutive~~set ~~business~~forth ~~days~~by ~~during~~specific ~~the~~reference ~~180-calendar~~in ~~day~~such ~~grace~~a ~~period~~filing.

IfItem ~~the Company is not in compliance by July 28, 2026, the Company may be afforded a second 180-calendar day period to regain compliance~~9.01 Financial ToStatements ~~qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares~~ and ~~all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement~~Exhibits. In addition, the Company would be required to notify Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary.

If(d) the Company does not regain compliance within the allotted 180-day compliance period and is not eligible for a second 180-day compliance period, the Company’s common stock would be subject to delisting unless it requested a hearing before an independent Nasdaq Hearings PanelExhibits. ~~A request for a hearing would stay any suspension or delisting action pending the hearing and any additional extension period granted by the Nasdaq Hearings Panel.~~

The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options to resolve the non-compliance with the minimum bid price requirement. The Company’s receipt of the notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission. However, there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.Exhibit

~~Forward-Looking Statements~~No. Document

~~This Current Report on Form 8-K may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995~~99.1 Press ~~These statements involve risks and uncertainty. Words such as “anticipate~~Release,” ~~“estimate,”~~dated ~~“expect,”~~April ~~“intend~~1,” ~~“plan,”~~2026 and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Such statements are based on the Company’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Investors are cautioned that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various risks and uncertainties. Investors should refer to the risks detailed from time to time in the reports the Company files with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other filings on Form 10-Q and periodic filings on Form 8-K, for additional factors that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TUHURA BIOSCIENCES, INC.
Date:	~~January~~April 301, 2026	By:	/s/ Dan Dearborn
			Name: Dan DearbornTitle: Chief Financial Officer

Filing Compare · TuHURA Biosciences, Inc./NV